



THE UNIVERSITY OF TEXAS  
**MD Anderson Cancer Center**  
Making Cancer History®

# PAN PACIFIC **LEUKEMIA** CONFERENCE

**Hyatt Regency Maui Resort and Spa**

**July 15-18, 2025**

**CALL FOR ABSTRACTS** — Deadline: Feb. 28, 2025



**[www.unmc.edu/cce/pan-pacific-leukemia](http://www.unmc.edu/cce/pan-pacific-leukemia)**



# Join Us for the Inaugural Pan Pacific Leukemia Conference

We cordially invite you to participate in the inaugural Pan Pacific Leukemia Conference, an exciting new chapter in leukemia treatment and research. Building on the success of the prestigious Pan Pacific Lymphoma Conference (PPLC), this conference aims to convene a diverse assembly of leading clinicians and researchers to share groundbreaking insights and foster interdisciplinary collaboration.

This gathering will delve into cutting-edge developments in leukemia research, explore innovative therapeutic modalities, and discuss the latest advancements in patient care. Attendees will have the unique opportunity to engage with fellow scholars and practitioners, and contribute to the ongoing discourse shaping leukemia treatment's future.

This landmark event, hosted by the University of Nebraska Medical Center in collaboration with The University of Texas MD Anderson Cancer Center, is intended for **oncologists, hematologists, pathologists, clinical scientists, advanced practice providers, nurses, and pharmacists**.

We encourage you to take this opportunity to connect, collaborate, and contribute to the advancement of leukemia care. Join us as we collectively push the boundaries of knowledge and improve outcomes for patients!

## Conference Directors



### Vijaya Raj Bhatt, MBBS, MS

Professor, Division of Oncology and Hematology; Medical Director, Leukemia Program; Section Leader, Malignant Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE



### Marina Konopleva, MD, PhD

Professor, Departments of Oncology and Molecular Pharmacology, Miriam Mandel Faculty Scholar in Cancer Research, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY



### Nitin Jain, MD

Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX



### Matthew A. Lunning, DO, FACP

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine; Assistant Vice Chancellor for Clinical Research, University of Nebraska Medical Center, Omaha, NE

## Call for Abstracts

The Directors of the Pan Pacific Leukemia Conference invite you to submit abstracts for the 2025 conference.

Ten submissions will be selected for physical poster presentations, while all other abstracts will be made available in print. Authors of selected abstracts are responsible for printing their posters. Additional information about the posters will be provided following the review and acceptance of the abstracts. It is also important to note that the presenting author must register for the conference.

For detailed information about abstract submission guidelines and requirements, please visit [www.unmc.edu/cce/pan-pacific-leukemia](http://www.unmc.edu/cce/pan-pacific-leukemia).

**The deadline for abstract submission is February 28, 2025.**

**Abstract Acceptance:** Authors will receive notification of abstract acceptance via email by March 14, 2025.

## Travel Stipend

The Pan Pacific Leukemia Conference is pleased to offer a limited number of stipends for fellows-in-training, junior faculty members\*, and nurses whose abstracts have been accepted for presentation.

To be considered for a travel stipend, please submit a letter from your department chair, chief of staff, or director verifying your status along with your abstract.

Stipend awards will include the following benefits:

- Waiver of the conference registration fee
- Coverage of two nights' lodging plus tax at the Hyatt Regency Maui, paid directly by the conference

Please note that stipend recipients must stay at the Hyatt Regency Maui to qualify for the stipend. No direct funds will be disbursed.

\*Junior faculty is defined as a faculty member of three years or less.

## Conference Objectives

At the conclusion of the conference, the participants should be better able to:

1. Discuss pathological and molecular advances in acute myeloid leukemia, myelodysplastic syndrome, myeloproliferative neoplasms, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and clonal hematopoiesis, and their incorporation into clinical practice.
2. Learn about newer therapeutic strategies in acute leukemias, chronic leukemias, myelodysplastic syndrome, and myeloproliferative disorders.
3. Describe advances in Chimeric Antigen Receptor (CAR) T-cell therapy for acute lymphocytic leukemia.
4. Describe the emerging role of doublets and triplets combination targeted therapies in CLL.
5. Describe the role of upfront allogeneic stem cell transplantation in acute leukemias and myelodysplastic syndrome.
6. Identify the importance of supportive care in the management of acute leukemias, myeloid malignancies, and allogeneic stem cell transplantation.

## Participant Registration Fee

The participant registration fee covers access to all scientific sessions, breakfasts, the welcome reception on Tuesday, the conference dinner on Thursday, and continuing education credits.

	By April 11	After April 11
Physicians	\$500	\$600
Other Health Care Providers	\$350	\$450
Pharmaceutical/Health Care Industry Representative	\$850	\$1000

### Registration Deadline: June 13, 2025

Once online registration is closed, you will only be able to register on-site for the following walk-in fee:

- Physicians – \$750
- Other Health Care Providers – \$600
- Pharmaceutical/Health Care Industry Representatives – \$1150

Walk-in registrations will only be accepted if space is available.

Scan to  
register!



## Accompanying Guest Fee

The fee for each accompanying guest aged 13 and older is \$250. There is no charge for children 12 and under. Accompanying guests are welcome to join conference registrants at the following meal functions:

- Welcome reception on Tuesday evening
- Conference dinner on Thursday evening
- Continental breakfasts and breaks during the main conference (Tuesday through Friday)

Please note that name tags will be issued and must be worn by all attendees at these meal functions.

**Full payment must accompany each conference registration.**

## Cancellation/Refund Policy

If you need to cancel your registration, please email [registrationCCF@unmc.edu](mailto:registrationCCF@unmc.edu) no later than June 13, 2025. A \$250 processing fee applies to cancellations made by June 13, 2025. Cancellations made after this date, as well as registrants who do not attend, will be responsible for the full conference registration fee.

## Substitutions

You may transfer your registration to a colleague by emailing [pplc@unmc.edu](mailto:pplc@unmc.edu) by June 13, 2025. Please include your name and email address, along with the name, email address, and phone number of the person who will attend in your place. Note that only one substitution is permitted.

## Questions?

Send an email to [pplc@unmc.edu](mailto:pplc@unmc.edu).

Missy Edwards  
Educational Projects Coordinator  
Center for Continuing Education  
University of Nebraska Medical Center

Brenda Ram, CMP, CHCP  
Director of Educational Programs  
Center for Continuing Education  
University of Nebraska Medical Center



# Conference Agenda

*Tuesday, July 15*

7:00 a.m. Conference Registration / Continental Breakfast

7:30 a.m. Introduction

7:45 a.m. Welcome Address  
Vijaya Raj Bhatt, MBBS, MS; Nitin Jain, MD; Marina Konopleva, MD, PhD;  
and Matthew Lunning, DO, FACP

## Acute Myeloid Leukemia (AML)

Moderators: Vijaya Raj Bhatt, MBBS, MS and Heidi D. Klepin, MD, MS

8:00 a.m. World Health Organization (WHO) Classification in AML  
and Myelodysplastic Syndrome (MDS)  
Joseph D. Khoury, MD

8:15 a.m. Harmonizing WHO and International Consensus  
Classification (ICC) Classification in AML and MDS  
Sanam Loghavi, MD

8:30 a.m. Measurable Residual Disease (MRD) in AML: What Are  
the Implications?  
Jerald P. Radich, MD

8:45 a.m. Geriatric Assessment in Leukemia: Why Should You Care?  
Vijaya Raj Bhatt, MBBS, MS

9:00 a.m. Questions and Answers

## Choosing Wisely: Upfront Treatment Intensity Selection in Adults with AML

### Intensive Chemotherapy in Adults

9:15 a.m. Yes, and I Go Beyond 7+3  
Richard M. Stone, MD

9:30 a.m. No, I Use Lower Intensity Chemotherapy  
Keith W. Pratz, MD

### Intensive Chemotherapy in Younger Adults

9:45 a.m. Yes, I Integrate Novel Therapies with Intensive  
Chemotherapy  
Tapan M. Kadia, MD

10:00 a.m. No, It is Prime Time for Upfront Lower Intensity Triplet  
Therapies  
Eunice S. Wang, MD

10:15 a.m. Questions and Answers

10:30 a.m. Break

## Debate/Discussion: Treatment Options for Relapsed or Refractory (R/R) AML

Moderators: Joann B. Sweasy, PhD and Geoffrey L. Uy, MD

10:50 a.m. Targeted Therapies in R/R AML  
Naval G. Daver, MD

11:05 a.m. Targeted Radiotherapies and Other Novel Therapies in  
R/R AML  
Geoffrey L. Uy, MD

11:20 a.m. Immediate Allogeneic Transplant  
Krishna Gundabolu, MBBS, MS

11:35 a.m. Questions and Answers

11:50 a.m. Lunch Break (On Your Own)

## Interprofessional Education

Moderators: Katherine L. Byar, MSN, ANP, BC, BMTCN® and Kim Schmit-Pokorny, MSN, RN,  
OCN®, BMTCN®

1:00 p.m. Managing Platelet Refractoriness During Intensive  
Antileukemia Chemotherapy  
Aleh (Oleg) Bobr, MD

1:15 p.m. Safely Using New and Targeted Therapies for Acute  
Myeloid Leukemia  
Allison M. Graner, PharmD, BCOP and Caitlin R. Rausch, PharmD, BCOP

1:45 p.m. Mitigating Risks of Intensive Acute Lymphoblastic  
Leukemia (ALL) Therapies and Monoclonal Antibodies  
Jared E. Matya, PharmD, BCOP and Shilpa Paul, PharmD, BCOP

2:15 p.m. Supportive Care in Older Adults with Hematological  
Malignancies  
Kah Poh Loh, BMedSci, MBBCh, BAO, MS

2:30 p.m. Team Science Approach to Managing Patients with  
Leukemia  
Katherine L. Byar, MSN, ANP, BC, BMTCN®

2:45 p.m. Supporting Adolescent/Young Adult (AYA) Patients  
Undergoing Leukemia Treatment and Transitioning Care  
from Pediatric to Adult Teams  
Kimberly Miller, BSN, RN, BMTCN® and Rachael L. Schmidt, DNP, FNP-C,  
AOCNP®

3:00 p.m. Questions and Answers

3:15 p.m. Adjourn

## Welcome Reception

7:00-9:00 p.m.

Conference participants and registered accompanying guests are  
invited to join. Name badges required.







## Wednesday, July 16

7:00 a.m. Continental Breakfast

### Acute Lymphoblastic Leukemia (ALL)

Moderators: Ryan D. Cassaday, MD and Nitin Jain, MD

7:45 a.m. **Keynote Address**

Progress in Adult ALL: Last 10 Years and the Future Ahead  
Hagop M. Kantarjian, MD

8:15 a.m. What Have We Learned from Genetics of B-ALL and T-ALL?  
Charles G. Mullighan, MBBS (Hons), MSc, MD

8:30 a.m. Questions and Answers

### How Do I...

8:45 a.m. How Do I Treat Adults with Newly Diagnosed Ph-Negative B-ALL?  
Marlise R. Luskin, MD, MSCE

9:00 a.m. How Do I Treat Central Nervous System Disease in ALL?  
Ryan D. Cassaday, MD

9:15 a.m. How Do I Use CAR-T in Adult ALL?  
Lori Muffly, MD, MS

9:30 a.m. How Do I Use CAR-T in Pediatric ALL?  
Stephan A. Grupp, MD, PhD

9:45 a.m. Questions and Answers

10:00 a.m. Break

### Chemotherapy Options for Upfront Management of ALL

10:20 a.m. Use of Asparaginase in ALL – When and How  
Wendy Stock, MD

10:35 a.m. Chemotherapy-Free Regimens for Ph-Positive ALL  
Elias Jabbour, MD

10:50 a.m. BCL2 and BCL-XL Inhibition in ALL – Ready for Primetime?  
Marina Konopleva, MD, PhD

11:05 a.m. Questions and Answers

### Myeloproliferative Neoplasms (MPN)

Moderators: Laura C. Michaelis, MD and Naveen Pemmaraju, MD

11:20 a.m. How Many Janus Kinase (JAK) Inhibitors Do We Need in Myelofibrosis (MF)?  
Ruben Mesa, MD, FACP

11:35 a.m. Can We Modify the Disease in MF? How?  
Naveen Pemmaraju, MD

11:50 a.m. What's New in Polycythemia Vera?  
Olatoyosi Odenike, MD

12:05 p.m. What's New in Essential Thrombocythaemia?  
Laura C. Michaelis, MD

12:20 p.m. Questions and Answers

12:35 p.m. Lunch Break (On Your Own)

### Meet the Experts

3:00 p.m. Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS)  
Moderator: Vijaya Raj Bhatt, MBBS, MS  
Experts: Geoffrey L. Uy, MD; Eunice S. Wang, MD; and Olatoyosi Odenike, MD

4:00 p.m. Chronic Lymphocytic Leukemia (CLL)  
Moderator: Nitin Jain, MD  
Experts: Julie M. Vose, MD, MBA; Susan M. O'Brien, MD; and Matthew A. Lunning, DO, FACP

5:00 p.m. Adjourn

## Thursday, July 17

7:00 a.m. Continental Breakfast

### Myelodysplastic Syndrome (MDS) and Clonal Hematopoiesis

Moderators: Olatoyosi Odenike, MD and Mikkael A. Sekeres, MD, MS

7:45 a.m. Molecular International Prognostic Scoring System (IPSS-M): How Does It Affect Treatment Selection?  
Elli Papaemmanuil, PhD

8:00 a.m. Biology of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Clonal Cytopenia of Undetermined Significance (CCUS)  
Mrinal S. Patnaik, MBBS

8:15 a.m. Improving the Health of Patients with CHIP/CCUS  
Uma Borate, MD, MBBS

# Conference Agenda (continued)

8:30 a.m. Cellular Therapy in AML and MDS: Are We Lagging Behind or Making Progress?  
Naval G. Daver, MD

8:45 a.m. Questions and Answers

9:00 a.m. How I Treat MDS in 2025  
Guillermo Garcia-Manero, MD

9:15 a.m. Treatment of Lower Risk MDS: Erythropoiesis-Stimulating Agents (ESA) and Beyond  
Jacqueline S. Garcia, MD

9:30 a.m. Moving Beyond Hypomethylating Agent in Higher Risk MDS: Lessons Learned From Prior Failures  
Amer M. Zeidan, MBBS, MHS

9:45 a.m. Triplet Therapies in MDS  
Mikhael A. Sekeres, MD, MS

10:00 a.m. Managing Chronic Myelomonocytic Leukemia (CMML)  
Guillermo Montalbán Bravo, MD

10:15 a.m. Questions and Answers

10:30 a.m. Break

## To Transplant or Not to Transplant?

Moderators: Krishna Gundabolu, MBBS, MS and Mary M. Horowitz, MD, MS

10:50 a.m. Transplanting Lower Risk MDS: Are There Any Patients Who Would Benefit?  
Marcos J. de Lima, MD

11:05 a.m. Transplanting Higher Risk MDS: Should Any Patients Not Be Transplanted?  
Mary M. Horowitz, MD, MS

11:20 a.m. Upfront vs. Delayed Transplant for AML in Era of Novel Treatments and Maintenance Therapy  
Upfront: Vijaya Raj Bhatt, MBBS, MS  
Delayed: Andrew Wei, MBBS, PhD

11:50 a.m. Questions and Answers

12:05 p.m. Lunch Break (On Your Own)

## Ask the Experts

### Allogeneic Stem Transplantation

Moderators: Partow Kebriaei, MD and Catherine E. Lai, MD, MPH

1:00 p.m. Supportive Care in Older Adults Undergoing Transplant  
Tanya M. Wildes, MD, MSCl

1:15 p.m. Acute Lymphoblastic Leukemia (ALL) Transplant: Upfront Indications and Consolidation Transplant Post-CAR T-Cell  
Partow Kebriaei, MD

1:30 p.m. Improving Outcomes of Patients with Myelofibrosis Who Need Transplant  
Nicolaus M. Kröger, MD

1:45 p.m. Preventing Post-Transplant Relapses  
Marcos J. de Lima, MD

2:00 p.m. Immune Reconstitution After Allogeneic Transplant  
Krishna Komanduri, MD

2:15 p.m. Prevention of Chronic Graft-Versus-Host Disease  
Shannon R. McCurdy, MD

2:30 p.m. Questions and Answers

2:45 p.m. Break

## Meet the Experts

3:00 p.m. Acute Lymphoblastic Leukemia (ALL)c  
Moderator: Marlise R. Luskin, MD, MSCE  
Experts: Stephan A. Grupp, MD, PhD; Lori Muffy, MD, MS; and Nitin Jain, MD

4:00 p.m. Myeloproliferative Neoplasms (MPN)  
Moderator: Naveen Pemmaraju, MD  
Experts: Ruben Mesa, MD, FACP; Jacqueline S. Garcia, MD; and Laura C. Michaelis, MD

5:00 p.m. Adjourn

## Conference Dinner

7:00-10:00 p.m.

Conference participants and registered accompanying guests are invited to join. Name badges required.

## Friday, July 18

7:00 a.m. Continental Breakfast

## Chronic Myelogenous Leukemia (CML)

Moderators: Jane F. Apperley, MBChB, MD, FRCP, FRCPath and Jorge E. Cortes, MD

7:45 a.m. Response Assessment in CML  
Jerald P. Radich, MD

8:00 a.m. Tyrosine Kinase Inhibitor (TKI) in Upfront Management of CML: Is One Superior to Others?  
Michael M. Haddadin, MBBS

8:15 a.m. Management of CML Not Meeting Milestones  
Fadi Haddad, MD



## Accreditation



In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 23.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### NURSES

The University of Nebraska Medical Center designates this activity for up to 23.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

### PHARMACISTS


The University of Nebraska Medical Center designates this activity for 23.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity.

## Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 23.75 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
- 23.75 MOC points in the American Board of Pathology's (ABPATH) Maintenance of Certification (MOC) program.

It is the CME Provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.



8:30 a.m.	3rd Generation ABL1 Kinase Inhibitors – When and How to Use Them Jorge E. Cortes, MD
8:45 a.m.	Questions and Answers
9:00 a.m.	Stopping Tyrosine Kinase Inhibitor in CML: When and How Jorge E. Cortes, MD
9:15 a.m.	Mitigating Toxicities Associated with TKI Jane F. Apperley, MBChB, MD, FRCP, FRCPath
9:30 a.m.	Questions and Answers
9:45 a.m.	Break

### Chronic Lymphocytic Leukemia (CLL)

Moderators: Matthew Lunning, DO, FACP and Julie M. Vose, MD, MBA

#### Optimal Upfront Treatment in CLL: A Moving Target

10:05 a.m. Younger Patients  
R. Gregory Bociek, MD, MSc, FRCP(C)

10:20 a.m. Older Patients  
Nitin Jain, MD

10:35 a.m. Questions and Answers

#### Management of Relapsed CLL

10:50 a.m. Moving CAR T-Cell Therapy to the Center: Lessons Learned in Lymphoma  
Matthew Lunning, DO, FACP

11:05 a.m. Double Refractory CLL: An Emerging Clinical Challenge  
Susan M. O'Brien, MD

11:20 a.m. Richter Transformation  
William G. Wierda, MD, PhD

11:35 a.m. Questions and Answers

11:50 a.m. Concluding Remarks  
Matthew Lunning, DO, FACP

12:00 p.m. Adjourn

# Conference Faculty

**Jane F. Apperley, MBChB, MD, FRCP, FRCPath**

Faculty of Medicine, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom

**Vijaya Raj Bhatt, MBBS, MS★**

Professor; Medical Director, Leukemia Program, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Aleh (Oleg) Bobr, MD**

Assistant Professor; Medical Director, Blood Bank and Tissue Services; Medical Director, Quality, Compliance, and Process Improvement; Medical Director, Regional Pathology Services; Associate Director of Apheresis Service; Consultant, Coagulation Testing Services, Department of Pathology, Microbiology and Immunology, University of Nebraska Medical Center, Omaha, NE

**R. Gregory Bociek, MD, MSc, FRCP(C)**

Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Uma Borate, MD, MBBS**

Associate Professor, Division of Hematology, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

**Katherine L. Byar, MSN, ANP, BC, BMTCN®**

Nurse Practitioner, Nebraska Medicine, Omaha, NE

**Ryan D. Cassaday, MD**

Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine; Associate Professor, Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA

**Jorge E. Cortes, MD**

Director, Georgia Cancer Center; Professor, Department of Medicine; Cecil F. Whitaker Jr. GRA Eminent Scholar Chair in Cancer, Medical College of Georgia, Augusta University, Augusta, GA

**Naval G. Daver, MD**

Professor and Director, Leukemia Research Alliance Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Marcos J. de Lima, MD**

Professor, Division of Hematology; Director of the Blood and Bone Marrow Transplant and Cellular Therapy Program, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH

**Jacqueline S. Garcia, MD**

Assistant Professor of Medicine, Harvard Medical School; Assistant Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

**Guillermo Garcia-Manero, MD**

Professor; Chief, Section of Myelodysplastic Syndromes; Deputy Chair, Translational Research; Fellowship Program Director, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Allison M. Graner, PharmD, BCOP**

Oncology Pharmacist, Nebraska Medicine, Omaha, NE

**Stephan A. Grupp, MD, PhD**

Yetta Deitch Novotny Endowed Chair in Pediatric Oncology; Section Chief of the Cellular Therapy and Transplant Section; Inaugural Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy; Medical Director of the Cell and Gene Therapy Laboratory and Children's Hospital of Philadelphia, Philadelphia, PA

**Krishna Gundabolu, MBBS, MS**

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Fadi Haddad, MD**

Assistant Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Michael M. Haddadin, MBBS**

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Mary M. Horowitz, MD, MS**

Robert A. Uihlein Jr. Professor of Hematologic Research; Director, Center for International Blood & Marrow Transplant Research; Associate Director, Cancer, Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, WI

**Elias Jabbour, MD**

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Nitin Jain, MD★**

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Tapan M. Kadia, MD**

Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Hagop M. Kantarjian, MD**

Professor and Chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Partow Kebriaei, MD**

Professor, Division of Cancer Medicine, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX

**Joseph D. Khoury, MD**

Stokes-Shackelford Professor and Chair, Department of Pathology, Microbiology, and Immunology, University of Nebraska Medical Center, Omaha, NE

**Heidi D. Klepin, MD, MS**

Professor, Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC

**Krishna Komanduri, MD**

Julius R. Krevans, MD Distinguished Professorship in Internal Medicine; Professor and Chief, Division of Hematology and Oncology, Department of Medicine; Physician-in-Chief, Helen Diller Family Comprehensive Cancer Center; Clinical Director, Living Therapeutics Initiative, University of California San Francisco, San Francisco, CA

**Marina Konopleva, MD, PhD★**

Director, Leukemia Program; Co-Director, Blood Cancer Institute, Montefiore Einstein Comprehensive Cancer Center; Professor, Oncology and Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY

**Nicolaus M. Kröger, MD**

Professor of Medicine; Medical Director, Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany

**Catherine E. Lai, MD, MPH**

Associate Professor of Clinical Medicine; Physician Leader, Leukemia Clinical Research Unit, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**Sanam Loghavi, MD**

Assistant Professor, Division of Pathology/Lab Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX

**Kah Poh Loh, BMedSci, MBBCh, BAO, MS**

Assistant Professor, Division of Hematology and Oncology, Department of Medicine, University of Rochester Medical Center, Rochester, NY

**Matthew Lunning, DO, FACP★**

Assistant Vice Chancellor of Clinical Research; Associate Vice Chair of Research; Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE





**Marlise R. Luskin, MD, MSCE**

Assistant Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

**Jared E. Matya, PharmD, BCOP**

Clinical Pharmacist Practitioner, Blood and Marrow Transplant/Cellular Therapy, Nebraska Medicine, Omaha, NE

**Shannon R. McCurdy, MD**

Assistant Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**Ruben Mesa, MD, FACP**

President and Executive Director, Atrium Health Levine Cancer Institute and Atrium Health Wake Forest Baptist Comprehensive Cancer Center; Vice Dean for Cancer Programs and Professor of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC

**Laura C. Michaelis, MD**

Professor of Medicine, Division of Hematology-Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI

**Kimberly Miller, BSN, RN, BMTCN®**

Manager Blood and Marrow Transplantation and CAR T Program, Nebraska Medicine, Omaha, NE

**Guillermo Montalbán Bravo, MD**

Assistant Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Lori Muffy, MD, MS**

Associate Professor of Medicine, Blood and Marrow Transplantation & Cellular Therapy Division, Stanford School of Medicine, Stanford University, Stanford, CA

**Charles G. Mullighan, MBBS (Hons), MSc, MD**

Member, St. Jude Faculty; Deputy Director, Comprehensive Cancer Center; Co-Leader, Hematological Malignancies Program; Medical Director, St. Jude Biorepository; William E. Evans Endowed Chair, Department of Pathology, St. Jude Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital Comprehensive Cancer Center, Memphis, TN

**Susan M. O'Brien, MD**

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research; Professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, Irvine, CA

**Olatoyosi Odenike, MD**

Professor of Medicine; Director, Leukemia Program; Division of Hematology/Oncology, Department of Medicine, University of Chicago Medicine, Chicago, IL

**Elli Papaemmanuil, PhD**

Associate Attending, Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY

**Mrinal S. Patnaik, MBBS**

Physician Scientist, Division of Hematology, Department of Internal Medicine; Chair, Acute Leukemia and Myeloid Neoplasms Group; Scientific Director, Epigenetics Developmental Laboratory and the Epigenomics Program, Mayo Clinic, Rochester, MN

**Shilpa Paul, PharmD, BCOP**

Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX

**Naveen Pemmaraju, MD**

Professor, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Keith W. Pratz, MD**

Associate Professor of Medicine; Section Chief, Leukemia; Director, Leukemia Program, Division of Hematology-Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**Jerald P. Radich, MD**

Professor, Translational Science & Therapeutics Division; Kurt Enslein Endowed Chair; Professor, Division of Hematology and Oncology, Fred Hutch Cancer Center, University of Washington School of Medicine, Seattle, WA

**Caitlin R. Rausch, PharmD, BCOP**

Clinical Pharmacy Specialist, The University of Texas MD Anderson Cancer Center, Houston, TX

**Rachael L. Schmidt, DNP, FNP-C, AOCNP®**

Program Director, Survivorship and Cancer Risk and Prevention; Assistant Director, Health Promotion and Screening, Office of Community Outreach and Engagement Health Promotion Unit, The Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

**Kim Schmit-Pokorny, MSN, RN, OCN®, BMTCN®**

Director BMT, CAR T, Cellular Therapy and Gene Therapy Program, Nebraska Medicine, Omaha, NE

**Mikhael A. Sekeres, MD, MS**

Professor of Medicine and Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami Health System, Miami, FL

**Wendy Stock, MD**

Anjali Seth Nayak Professor of Medicine, Division of Biological Sciences, Department of Medicine, University of Chicago, Chicago, IL

**Richard M. Stone, MD**

Director of the Adult Acute Leukemia Program, Dana-Farber Cancer Institute, Boston, MA

**Joann B. Sweasy, PhD**

Director, Fred & Pamela Buffett Cancer Center; Director, Eppley Institute for Research in Cancer and Allied Diseases; Professor, Eppley Institute, University of Nebraska Medical Center, Omaha, NE

**Geoffrey L. Uy, MD**

Professor, Division of Oncology, John T. Milliken Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO

**Julie M. Vose, MD, MBA**

Division Chief and George and Peggy Payne Distinguished Chair of Oncology, Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Eunice S. Wang, MD**

Chief of the Leukemia Service, Roswell Park Comprehensive Cancer Center, Buffalo, NY

**Andrew Wei, MBBS, PhD**

Professor; Adjunct Professor (Research), Australian Centre for Blood Diseases, Monash University, Victoria, Australia

**William G. Wierda, MD, PhD**

Professor of Medicine; Jane and John Justin Distinguished Chair in Leukemia Research in Honor of Dr. Elihu Estey; Section Chief, Chronic Lymphocytic Leukemia; Center Medical Director; Executive Medical Director, Inpatient Medical Services; Deputy Department Chair, Division of Cancer Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

**Tanya M. Wildes, MD, MSCI**

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

**Amer M. Zeidan, MBBS, MHS**

Associate Professor, Section of Hematology, Department of Internal Medicine, Yale Cancer Center and Smilow Cancer Hospital, New Haven, CT

**★ Conference Director**

# Hotel and Travel

## Hotel Accommodations



### Hyatt Regency Maui Resort and Spa

200 Nohea Kai Dr, Lahaina, HI 96761

A block of rooms has been reserved at the Hyatt Regency Maui Resort and Spa from Saturday, July 12, through Monday, July 21, 2025.

### ROOM RATES (SINGLE/DOUBLE OCCUPANCY)

Rates below include the \$20 daily resort fee

- Resort/Golf Mountain View — \$500
- Partial Ocean View — \$519
- Deluxe Ocean View — \$550

The maximum occupancy per room is 4.

There is no charge for children 18 years and under sharing the same room as the parents and using existing bedding (1 king or 2 queen beds).

### Other Charges

- **Additional person over 18 years old** – \$80 per night is applied to individual folio
- **Porterage** – \$14 per person (includes children of all ages) plus Hawaii state tax. This rate is based on two bags per person. This charge is automatically posted to the individual folio.
- **Housekeeping gratuities** are up to the individual's discretion, \$6 per room, per day, is recommended.

### RESERVATION METHOD

- To ensure that only registered participants are able to use the conference-contracted hotel rates, **the link to make your hotel reservation will be included in the email confirming your conference registration.** If you do not receive this email within 48 hours of your registration, please contact us at [pplc@unmc.edu](mailto:pplc@unmc.edu).
- A two-night deposit for all reservations will be taken at the time of booking.
- **The block rate is available on a first-come, first-served basis until April 11, 2025.** After this date, reservations will be accepted on a space and rate availability basis.

### HOTEL CANCELLATION POLICY

- **30 to 7 days prior to arrival:** All cancellations received within this time period will be assessed a two nights room deposit, plus applicable taxes.
- **7 days up to arrival date:** All cancellations received within this time period as well as no-shows will be assessed the cost of the full length of the stay, plus applicable taxes.



## *Airport/Travel Information*

The two closest airports to the Hyatt Regency Maui Resort and Spa are Kahului Airport/OGG (approximately 27 miles) and Kapalua West Maui Airport/JHM (approximately 4 miles).

## *Conference Attire*

Casual dress is encouraged for the entire conference. Layered clothing is recommended as the temperature in meeting rooms can fluctuate. A light jacket or sweater for outdoor evening activities is suggested.

## *Maui*

Maui is often regarded as the best Hawaiian island to visit, primarily due to its stunning beaches and diverse landscapes. Notable spots include the famous Kaanapali Beach, where visitors can enjoy swimming and sunbathing. The island features 48 miles of coastline, over 80 unique beaches, and breathtaking scenery, including lush valleys and majestic mountains, all ideal for outdoor activities like whale watching and hiking in Haleakala National Park.

Known as “The Valley Isle,” Maui captivates with its natural beauty and rich cultural heritage. Visitors can experience vibrant agricultural lands, local farmers’ markets, and traditional Hawaiian luaus, blending the island’s stunning landscapes with its warm community spirit. This combination of adventure and cultural experiences makes Maui a memorable destination for travelers.







University of Nebraska Medical Center  
Center for Continuing Education  
986800 Nebraska Medical Center  
Omaha, NE 68198-6800

CID 61806

NON PROFIT  
US POSTAGE  
P A I D  
OMAHA, NE  
PERMIT NO. 454

# PAN PACIFIC LEUKEMIA CONFERENCE

July 15-18, 2025 • Hyatt Regency Maui

Register by April 11  
to receive the discounted rate!

*Scan to  
register!*



[www.unmc.edu/cce/pan-pacific-leukemia](http://www.unmc.edu/cce/pan-pacific-leukemia)